Secretive ‘rebate trap’ keeps generic drugs for diabetes and other ills out of reach

Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.

Why the U.S. remains the world’s most expensive market for ‘biologic’ drugs

Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.

Workers used to benefit from innovation. Can that happen again?

Machines can make jobs better, but a tiny class of bosses uses them to make jobs disappear. It doesn’t have to be this way.

The math on why the Trump administration’s fuel standards report is seriously flawed

The Trump administration’s analysis finds costs of current standards exceed the benefits by over $170 billion – but it includes four major errors in the calculations.

US-China trade war truce: 2 reasons why it’s unlikely to last

With the two leaders’ approach to the world looking increasingly different, it’s likely that the G-20 truce will merely have paused the trade war – not stopped it.

Black Friday isn’t the only time workers face unfair schedules

Nearly half of retail workers reported having to work on Thanksgiving, and big employers are far more likely to have their workers on duty than are smaller ones.